| ［1］ |
Wang X，Xia C，Wang Y，et al. Landscape of young breast cancer under 35 years in China over the past decades：a multicentre retrospective cohort study （YBCC-Catts study） ［J］. EClinicalMedicine，2023，64：102243.
|
| ［2］ |
Barzaman K，Karami J，Zarei Z，et al. Breast cancer：biology，biomarkers，and treatments ［J］. Int Immunopharmacol，2020，84：106535.
|
| ［3］ |
Paijens ST，Vledder A，De Bruyn M，et al. Tumor-infiltrating lymphocytes in the immunotherapy era ［J］. Cell Mol Immunol，2021，18（4）：842-859.
|
| ［4］ |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南-2025［M］. 北京：人民卫生出版社，2025.
|
| ［5］ |
Sarnaik AA，Hwu P，Mulé JJ，et al. Tumor-infiltrating lymphocytes：a new hope ［J］. Cancer Cell，2024，42（8）：1315-1318.
|
| ［6］ |
Bergman PJ. Cancer immunotherapy ［J］. Vet Clin North Am Small Anim Pract，2024，54（3）：441-468.
|
| ［7］ |
Williams AD，Payne KK，Posey AD Jr，et al. Immunotherapy for breast cancer：current and future strategies ［J］. Curr Surg Rep，2017，5（12）：31.
|
| ［8］ |
Keshavarz S，Wall JR，Keshavarz S，et al. Breast cancer immunotherapy：a comprehensive review ［J］. Clin Exp Med，2023，23（8）：4431-4447.
|
| ［9］ |
Schmid P，Cortes J，Pusztai L，et al. Pembrolizumab for early triple-negative breast cancer ［J］. N Engl J Med，2020，382（9）：810-821.
|
| ［10］ |
Tas L，Jedema I，Haanen JBAG. Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes （TILs） for patients with solid cancers ［J］. Curr Opin Oncol，2023，35（2）：107-113.
|
| ［11］ |
Zemanek T，Nova Z，Nicodemou A. Tumor-infiltrating lymphocytes and adoptive cell therapy：state of the art in colorectal，breast and lung cancer ［J］. Physiol Res，2023，72（S3）：S209-S224.
|
| ［12］ |
Kazemi MH，Sadri M，Najafi A，et al. Tumor-infiltrating lymphocytes for treatment of solid tumors：It takes two to tango？ ［J］. Front Immunol，2022，13：1018962.
|
| ［13］ |
Salgado R，Denkert C，Demaria S，et al. The evaluation of tumor-infiltrating lymphocytes （TILs） in breast cancer：recommendations by an International TILs Working Group 2014 ［J］. Ann Oncol，2015，26（2）：259-271.
|
| ［14］ |
Ciarka A，Piątek M，Pęksa R，et al. Tumor-infiltrating lymphocytes （TILs） in breast cancer：prognostic and predictive significance across molecular subtypes ［J］. Biomedicines，2024，12（4）：763.
|
| ［15］ |
Garaud S，Dieu-Nosjean MC，Willard-Gallo K. T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy ［J］. Nat Commun，2022，13（1）：2259.
|
| ［16］ |
Yu Z，Shi J，Fang Y，et al. Developing innovative strategies of tumor-infiltrating lymphocyte therapy for tumor treatment ［J］. Oncol Rep，2024，51（6）：85.
|
| ［17］ |
Raskov H，Orhan A，Christensen JP，et al. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy ［J］. Br J Cancer，2021，124（2）：359-367.
|
| ［18］ |
Virassamy B，Caramia F，Savas P，et al. Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer ［J］. Cancer Cell，2023，41（3）：585-601. e8.
|
| ［19］ |
Guan Q，Han M，Guo Q，et al. Strategies to reinvigorate exhausted CD8+ T cells in tumour microenvironment ［J］. Front Immunol，2023，14：1204363.
|
| ［20］ |
Matossian MD，Shiang C，Dolcen DN，et al. High tumor glucocorticoid receptor expression in early-stage，triple-negative breast cancer is associated with increased T-regulatory cell infiltration ［J］. Breast Cancer Res Treat，2025，209（3）：563-572.
|
| ［21］ |
Barua S，Fang P，Sharma A，et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer ［J］. Lung Cancer，2018，117：73-79.
|
| ［22］ |
Leon-Ferre RA，Jonas SF，Salgado R，et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer ［J］. JAMA，2024，331（13）：1135-1144.
|
| ［23］ |
Denkert C，Von Minckwitz G，Darb-Esfahani S，et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer：a pooled analysis of 3771 patients treated with neoadjuvant therapy ［J］. Lancet Oncol，2018，19（1）：40-50.
|
| ［24］ |
Savas P，Virassamy B，Ye C，et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis ［J］. Nat Med，2018，24（7）：986-993.
|
| ［25］ |
Kim RS，Song N，Gavin PG，et al. Stromal tumor-infiltrating lymphocytes in NRG oncology/NSABP B-31 adjuvant trial for early-stage HER2-positive breast cancer ［J］. J Natl Cancer Inst，2019，111（8）：867-871.
|
| ［26］ |
Rayson VC，Harris MA，Savas P，et al. The anti-cancer immune response in breast cancer：current and emerging biomarkers and treatments ［J］. Trends Cancer，2024，10（6）：490-506.
|
| ［27］ |
Dieci MV，Miglietta F，Guarneri V. Immune infiltrates in breast cancer：recent updates and clinical implications ［J］. Cells，2021，10（2）：223.
|
| ［28］ |
Dvir K，Giordano S，Leone JP. Immunotherapy in breast cancer ［J］. Int J Mol Sci，2024，25（14）：7517.
|
| ［29］ |
Szekely B，Bossuyt V，Li X，et al. Immunological differences between primary and metastatic breast cancer ［J］. Ann Oncol，2018，29（11）：2232-2239.
|
| ［30］ |
Nederlof I，Rolfes AL，Gielen RCAM，et al. LBA11 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes （TILs） ［J］. Ann Oncol，2024，35：S1206.
|
| ［31］ |
Dieci MV，Bisagni G，Bartolini S，et al. Tumor-infiltrating lymphocytes and survival outcomes in early ERBB2 -positive breast cancer：10-year analysis of the shortHER randomized clinical trial ［J］. JAMA Oncol，2025，11（4）：386.
|
| ［32］ |
Dieci MV，Radosevic-Robin N，Fineberg S，et al. Update on tumor-infiltrating lymphocytes （TILs） in breast cancer，including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ：a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer ［J］. Semin Cancer Biol，2018，52（Pt 2）：16-25.
|
| ［33］ |
Criscitiello C，Guerini-Rocco E，Viale G，et al. Immunotherapy in breast cancer patients：a focus on the use of the currently available biomarkers in oncology ［J］. Anticancer Agents Med Chem，2022，22（4）：787-800.
|
| ［34］ |
Adams S，Schmid P，Rugo HS，et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer：cohort A of the phase II KEYNOTE-086 study ［J］. Ann Oncol，2019，30（3）：397-404.
|
| ［35］ |
Venetis K，Invernizzi M，Sajjadi E，et al. Cellular immunotherapy in breast cancer：the quest for consistent biomarkers ［J］. Cancer Treat Rev，2020，90：102089.
|
| ［36］ |
He L，Wang Y，Wu Q，et al. Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes：a meta-analysis ［J］. BMC Womens Health，2020，20（1）：194.
|
| ［37］ |
Loi S，Michiels S，Adams S，et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer：clinical utility in an era of checkpoint inhibition ［J］. Ann Oncol，2021，32（10）：1236-1244.
|
| ［38］ |
Zhao Y，Deng J，Rao S，et al. Tumor infiltrating lymphocyte （TIL） therapy for solid tumor treatment：progressions and challenges ［J］. Cancers （Basel），2022，14（17）：4160.
|
| ［39］ |
Zacharakis N，Huq LM，Seitter SJ，et al. Breast cancers are immunogenic：immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes ［J］. J Clin Oncol，2022，40（16）：1741-1754.
|
| ［40］ |
Yeong J，Goh D，Tan TJ，et al. Early triple-negative breast cancers in a Singapore cohort exhibit high PIK3CA mutation rates associated with low PD-L1 expression ［J］. Mod Pathol，2023，36（4）：100056.
|
| ［41］ |
张文静，周毅，冀亮. 肿瘤浸润淋巴细胞在乳腺癌诊治中的争议与共识 ［J］. 中国肿瘤临床，2025，52（5）：244-247.
|
| ［42］ |
Zaakouk M，Longworth A，Hunter K，et al. Detailed profiling of the tumor microenvironment in ethnic breast cancer，using tissue microarrays and multiplex immunofluorescence ［J］. Int J Mol Sci，2024，25（12）：6501.
|
| ［43］ |
Lu X，Jia Y，Zhang H，et al. Deep learning-based and BI-RADS guided radiomics model for automatic tumor-infiltrating lymphocytes evaluation in breast cancer ［J］. Br J Radiol，2024：tqae129. ［Epub ahead of print］.
|
| ［44］ |
Baharun NB，Adam A，Zailani MAH，et al. Automated scoring methods for quantitative interpretation of tumour infiltrating lymphocytes （TILs） in breast cancer：a systematic review ［J］. BMC Cancer，2024，24（1）：1202.
|
| ［45］ |
Finkelman BS，Zhang H，Hicks DG，et al. Tumor infiltrating lymphocytes in breast cancer：a narrative review with focus on analytic validity，clinical validity，and clinical utility ［J］. Hum Pathol，2025，162：105866.
|
| ［46］ |
Rosenberg SA，Packard BS，Aebersold PM，et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report ［J］. N Engl J Med，1988，319（25）：1676-1680.
|
| ［47］ |
Larkin J，Sarnaik A，Chesney JA，et al. Lifileucel （LN-144），a cryopreserved autologous tumor infiltrating lymphocyte （TIL） therapy in patients with advanced melanoma：Evaluation of impact of prior anti-PD-1 therapy ［J］. J Clin Oncol，2021，39（15 Suppl）：9505.
|
| ［48］ |
Lee HJ，Kim YA，Sim CK，et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer ［J］. Oncotarget，2017，8（69）：113345-113359.
|
| ［49］ |
Zacharakis N，Chinnasamy H，Black M，et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer ［J］. Nat Med，2018，24（6）：724-730.
|
| ［50］ |
Kumar A，Watkins R，Vilgelm AE. Cell therapy with TILs：training and taming T cells to fight cancer ［J］. Front Immunol，2021，12：690499.
|
| ［51］ |
Zhang P，Zhang G，Wan X. Challenges and new technologies in adoptive cell therapy ［J］. J Hematol Oncol，2023，16（1）：97.
|
| ［52］ |
Rosenbaum SR，Wilski NA，Aplin AE. Fueling the fire：inflammatory forms of cell death and implications for cancer immunotherapy ［J］. Cancer Discov，2021，11（2）：266-281.
|
| ［53］ |
Li J，Guo L，Feng Y，et al. Optical-magnetic imaging for optimizing lymphodepletion-TIL combination therapy in breast cancer ［J］. Mol Imaging Biol，2025，27（2）：260-273.
|
| ［54］ |
Zhang M，Li X，Zhou P，et al. Prediction value study of breast cancer tumor infiltrating lymphocyte levels based on ultrasound imaging radiomics ［J］. Front Oncol，2024，14：1411261.
|
| ［55］ |
Yamaguchi K，Nakazono T，Egashira R，et al. Relationship between kinetic parameters of ultrafast dynamic contrast-enhanced （DCE） MRI and tumor-infiltrating lymphocytes （TILs） in breast cancer ［J］. Jpn J Radiol，2025，43（1）：43-50.
|